Lumefantrine

113 interactions 7 explained in plain English
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Acetaminophen And Codeine Levofloxacin Oxaliplatin Injection Aripiprazole Injection Flecainide Dolasetron
75 Major 38 Moderate
All (113) Major (75) Moderate (38)

Major

Lumefantrine Goserelin Implant Zoladex Increased risk of QT interval prolongation Details Lumefantrine Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation Details Lumefantrine Granisetron Injection Granisol An increased risk of QT interval prolongation Details Lumefantrine Histrelin Implant Supprelin Increased risk of QT interval prolongation Details Lumefantrine Hydroxychloroquine Plaquenil Increased risk of QT interval prolongation Details Lumefantrine Inotuzumab Ozogamicin Injection Besponsa Increased risk of QT interval prolongation Details Lumefantrine Ivabradine Corlanor Increased risk of QT prolongation Details Lumefantrine Lefamulin Xenleta Increased artemether/lumefantrine exposure and an increased risk of QT prolongation Details Lumefantrine Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Lumefantrine Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Lumefantrine Levofloxacin Levaquin Increased risk of QT interval prolongation Details Lumefantrine Levofloxacin Injection Levaquin Increased risk of QT interval prolongation Details Lumefantrine Loperamide Diamode An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Lumefantrine Loratadine Agistam® Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Lumefantrine Maprotiline Ludiomil® Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Lumefantrine Mefloquine Lariam® Reduced lumefantrine exposure and an increased risk of QT interval prolongation Details Lumefantrine Metoclopramide Injection Gimoti Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Lumefantrine Metoclopramide Nasal Spray Gimoti Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Lumefantrine Metronidazole Flagyl An increased risk of QT interval prolongation Details Lumefantrine Metronidazole Injection Flagyl An increased risk of QT interval prolongation Details Lumefantrine Metronidazole Topical MetroCream® An increased risk of QT interval prolongation Details Lumefantrine Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation Details Lumefantrine Mexiletine Mexitil® Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Lumefantrine Moxifloxacin Avelox An increased risk of QT interval prolongation Details Lumefantrine Moxifloxacin Injection Avelox An increased risk of QT interval prolongation Details Lumefantrine Moxifloxacin Ophthalmic Moxeza® An increased risk of QT interval prolongation Details Lumefantrine Nebivolol Bystolic Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Lumefantrine Nevirapine Viramune Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine, and loss of antimalarial efficacy Details Lumefantrine Octreotide Bynfezia An increased risk of QT interval prolongation Details Lumefantrine Octreotide Injection Bynfezia An increased risk of QT interval prolongation Details Lumefantrine Ofloxacin Floxin® An increased risk of QT interval prolongation Details Lumefantrine Ofloxacin Ophthalmic Ocuflox An increased risk of QT interval prolongation Details Lumefantrine Ofloxacin Otic Floxin® Otic An increased risk of QT interval prolongation Details Lumefantrine Olodaterol Oral Inhalation Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Lumefantrine Oxaliplatin Injection Eloxatin® Increased risk of QT-interval prolongation Details

Moderate

Lumefantrine Asciminib Scemblix Increased artemether/lumefantrine exposure and an increased risk of potentiated QT prolongation Details Lumefantrine Belumosudil Rezurock Explained Increased artemether/lumefantrine exposure and an increased risk of potentiated QT prolongation Details Lumefantrine Bicalutamide Casodex Increased artemether/lumefantrine exposure and an increased risk of potentiated QT prolongation Details Lumefantrine Atorvastatin Atorvaliq Increased artemether/lumefantrine exposure and an increased risk of potentiated QT prolongation Details Lumefantrine Amlodipine Amvaz® Increased artemether/lumefantrine exposure and an increased risk of potentiated QT prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.